Amgen Highlights Data to Be Presented at ASCO
... neutropenia (neutropenia with fever) based on clinical practice. Another study compares the effectiveness of prophylactic versus delayed use of granulocyte colony-stimulating factors (G-CSFs), including NEUPOGEN(R) (filgrastim) and Neulasta, on neutropenia-related hospitalizations based on clinical ...Study Finds Blood Cells Can Be Reprogrammed to Act as Embryonic Stem Cells
... expressed genes for all three embryonic germ layers (the tissues from which all other tissue types in the body develop) and also produced myeloid and granulocyte colonies (types of white blood cells). The group confirmed that the reprogrammed cells had acquired ES cell characteristics by injecting the ...Human Heart Can Make New Cells
... they slowed the degradation of SDF-1, the main chemical that guides stem cells to damaged heart tissue. They also treated the mouse hearts with granulocyte colony stimulating factor, a drug that mobilizes stem cells from various places such as the bone marrow and blood. This two-pronged approach led to ...Scientists uncover indicator that warns leukemia is progressing to more dangerous form
... cells that carry BCR-ABL to the blast crisis stage. This stage is characterized by the over-production of beta-catenin in white blood cells called granulocyte macrophage progenitors (GMP) in effect, leukemia stem cells. According to Jamieson, a major roadblock in predicting and stopping the conversion ...Landmark Rh Immune Globulin Celebrates 40 Years of Saving Babies' Lives
... in any Rh-negative person after incompatible transfusion of Rh-positive blood or blood products (e.g., red blood cells, platelet concentrates, granulocyte concentrates) CONTRAINDICATIONS The use of RhoGAM and MICRhoGAM is contraindicated in Rh-positive individuals. ...Scientists identify new congenital neutropenia syndrome and causative gene mutation
... fighting infection. Children born with SCN suffer from frequent bacterial infections, and until the introduction of treatment with recombinant human granulocyte colony-stimulating factor (GCSF) in the 1990s, about three-fourths of affected children would die before 3 years of age. Treatment with GCSF usually ...Single microRNA fine-tunes innate immune response
... and dampening their activation. The study indicated that microRNA-223 targets Mefc2, a transcription factor that promotes the expansion of granulocyte cell progenitors. (Transcription factors are proteins that regulate gene expression.) By knocking out Mefc2, the authors found that some of the ...IDM Pharma Announces Data Presentation From Mifamurtide (L-MTP-PE) Compassionate Use Program
... (2 mg/m2 IV over 1 hour) was administered twice a week for 12 weeks followed by once a week for 24 weeks in combination with aerosol recombinant granulocyte monocyte colony stimulating factor (GM-CSF), an immune stimulating agent. In addition, some patients in the program were also treated with ...Their immune cells, fighting your cancer
... Academy of Sciences, DOI: 10.1073/pnas.0602382103). Cui hopes to begin human trials next summer in the US, when the immune systems of potential granulocyte donors will be at their peak. The concept of using immune cells from one person to fight cancer in another person is a very hot topic right now, ...White Blood Cell Booster May Help Cancer Patients Avoid Deadly Complications
... or halted when a patient's white blood cell count is too low, potentially leading to poorer outcomes, she added. "Patients taking a drug known as granulocyte colony-stimulating factor early in their chemotherapy were about half as likely to develop dangerously low white blood cell counts with fever, and ...IDM Pharma Announces Updated Data From Mifamurtide (L-MTP-PE) Compassionate Access Program
... followed by once a week for 24 weeks. In addition, some patients in the program were also treated with other agents including aerosol recombinant granulocyte monocyte colony stimulating factor (GM-CSF) an immune stimulating agent (n=20), ifosfamide (n=4), and/or gemcitabine (n=2). Results to date are ...Neutropenia: Biosimilar Product from India Moves One Step Closer to European Market
... of white blood cell) in the blood is too low - is a serious side effect of cancer chemotherapy and can prevent the treatment from being successful. granulocyte colony stimulating factor (G-CSF) is a human protein that can reverse neutropenia by initiating the production of neutrophils. Recombinant forms of ...Pixantrone to be Studied in Phase I/II Trial for Aggressive Multiple Sclerosis
... if this regimen results in lymphopenia of less than or equal to 1000/mm3. The doses and the number of infusions will be adapted to leukocyte, granulocyte and thrombocyte counts and possibly reduced. About Pixantrone Pixantrone (BBR 2778) is a novel DNA major groove binder that contains an ...Maxygen Announces Positive Progress in Phase IIa Clinical Trial of Novel PEG-GCSF
... be collected on the pharmacokinetic properties of MAXY-G34 and the mobilization of CD34+ stem cells. About MAXY-G34 MAXY-G34 is a novel pegylated granulocyte colony stimulating factor (PEG-GCSF) designed to treat chemotherapy-induced neutropenia. Preclinical and Phase I studies show MAXY-G34 to have novel ...PROCRIT(R) (Epoetin Alfa) Data to be Presented at American Society of Hematology Annual Meeting
... Oncology (ASCO) and ASH proceedings from 1990 to 2006 in transfusion-dependent MDS patients (n=578) treated with Epoetin alfa plus or minus granulocyte and granulocyte-macrophage colony stimulating factors (G/GM-CSF) assessed the efficacy of Epoetin alfa in achieving transfusion independence ...Study finds blood cells can be reprogrammed to act as embryonic stem cells
... expressed genes for all three embryonic germ layers (the tissues from which all other tissue types in the body develop) and also produced myeloid and granulocyte colonies (types of white blood cells). The group confirmed that the reprogrammed cells had acquired ES cell characteristics by injecting the newly ...Cell Therapy for Cardiovascular Diseases
... allogeneic mesenchymal stem cells for acute myocardial infarction will be presented by Dr. Joshua M. Hare MAGIC 5: combined approach using granulocyte colony stimulating factor (G-CSF), erythropoietin mobilization, and intracoronary cell infusion in patients with heart attack, presented in detail ...Top scientists meet for global conference on stem cell therapy for cardiovascular diseases
... mesenchymal stem cells for acute myocardial infarction will be presented by Dr. Joshua M. Hare MAGIC 5: combined approach using granulocyte colony stimulating factor (G-CSF), erythropoietin mobilization, and intracoronary cell infusion in patients with heart attack, presented in detail ...Fourth Annual International Conference on Cell Therapy for Cardiovascular Diseases
... allogeneic mesenchymal stem cells for acute myocardial infarction will be presented by Dr. Joshua M. Hare MAGIC 5: combined approach using granulocyte colony stimulating factor (G-CSF), erythropoietin mobilization, and intracoronary cell infusion in patients with heart attack, presented in detail ...Cloned mice created from fully differentiated cells, a milestone in cloning research
... for cloning mice using a fully differentiated blood cell called a granulocyte with its ancestor cells at different stages: hematopoietic stem cells, ... we can say with near certainty that a fully differentiated cell such as a granulocyte retains the genetic capacity for becoming like a seed that can give rise ...Researchers urge monitoring of bone health during chemotherapy
... to maintain strong bones." Weilbaecher and her colleagues found that when they gave mice an eight-day course of the growth factor, called granulocyte colony-stimulating factor (G-CSF), the mice lost bone mass and experienced increased bone tumor growth when injected with cancer cells. Their study ...Stem cell mobilization therapy appears to be ineffective in repairing damage caused by heart attack
... of cardiac tissue and the development of new blood vessels following a heart attack, thus opening up new prospects for stem-cell based therapies. granulocyte colony-stimulating factor (G-CSF, a growth-factor protein) induces mobilization of bone marrow stem cells, according to background information in the ...Recombinant DNA technology may enable oral, rather than injectable, delivery of protein drugs
... Transferrin, a plasma protein found in blood, can be fused with large, protein-based drugs such as granulocyte colony-stimulating factor (G-CSF) to create a new oral compound that is capable of surviving the journey through the gastrointestinal (GI) tract and ...Sysmex America Set to Launch New XT-Series(TM) Parameters
... (FDA) has cleared Sysmex's Immature granulocyte (IG) parameter and Reticulocyte Hemoglobin ... Analyzers provides a quantitative immature granulocyte count for metamyelocytes, myelocytes ... care. Prior to Sysmex's automated immature granulocyte counting, manual differential counting of ...Martek Announces First Quarter 2009 Financial Results
... of inflammation were improved, including: the number of circulating neutrophils; the concentrations of C-reactive protein ("CRP"); interleukin-6; and granulocyte monocyte-colony stimulating factor. There was a corresponding increase in the concentration of anti-inflammatory matrix metalloproteinase. The ...WEHI Spin-Out MuriGen Restructures G-CSF Antagonist Program With CSL
... and Zenyth Therapeutics Limited (now part of CSL Limited) and is developing therapeutic antibodies that inhibit the activity of the cytokine granulocyte colony stimulating factor (G-CSF). The collaboration built on the discovery by Professor Ian Wicks, a clinical rheumatologist at the Walter and ...Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008
... -- Follow-on Biologics Program -- Completed clinical trial demonstrating the bioequivalence of INS-19, the company's recombinant human granulocyte colony stimulating factor (G-CSF), to Neupogen(R), an FDA-approved G-CSF product for the treatment of neutropenia that recorded 2007 ...New Scrip Report Provides Strategic Insight on the Burgeoning Biosimilars Market
... The Report describes how companies are currently targeting products that are off-patent in Europe: in particular human growth hormone (hGH), EPO and granulocyte colony-stimulating factor (G-CSF). However, it points out that there are many more potential targets for development in areas that have so far ...Detection of mRNAs on Cryosections of the Cardiovascular System Using DIG-Labeled RNA Probes
... In research studies, it enables detection of the expression of rare mRNAs in the cardiovascular system (e.g., of the proinflammatory cytokine granulocyte macrophage colony stimulating factor [GM-CSF] in normal human coronary arteries, and of interleukin 6 [IL6] and glycoprotein gp130 in ...Human Granulocyte Macrophage Colony Stimulating Factor, Unconjugated from PeproTech
Description: ...